American Journal of Kidney Diseases
Volume 53, Issue 4 , Pages 572-575 , April 2009

Does Inflammation Fuel the Fire in CKD?

  • Dena E. Rifkin, MD, MS
    • ,
  • Mark J. Sarnak, MD, MS

      Affiliations

    • Corresponding Author InformationAddress correspondence to Mark J. Sarnak, MD, MS, Division of Nephrology, Tufts Medical Center, Box 391, 800 Washington St, Boston, MA 02111

References 

  1. Kannel WB, Dawber TR, Kagan A, Revotskie N, Stokes J. Factors of risk in the development of coronary heart disease—Six year follow-up experience (The Framingham Study). Ann Intern Med. 1961;55:33–50
  2. Stampfer MJ, Ridker PM, Dzau VJ. Risk factor criteria. Circulation. 2004;109:IV3–IV5
  3. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–1305
  4. Manjunath G, Tighiouart H, Coresh J, et al. Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. Kidney Int. 2003;63:1121–1129
  5. Goodpaster BH, Park SW, Harris TB, et al. The loss of skeletal muscle strength, mass, and quality in older adults: The Health, Aging and Body Composition Study. J Gerontol Series A Biol Sci Med Sci. 2006;61:1059–1064
  6. Kurella M, Lo JC, Chertow GM. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol. 2005;16:2134–2140
  7. Fried LF, Lee JS, Shlipak M, et al. Chronic kidney disease and functional limitation in older people: Health, Aging and Body Composition Study. J Am Geriatr Soc. 2006;54:750–756
  8. Hunsicker LG. The consequences and costs of chronic kidney disease before ESRD. J Am Soc Nephrol. 2004;15:1363–1364
  9. Elsayed EF, Tighiouart H, Griffith J, et al. Cardiovascular disease and subsequent kidney disease. Arch Intern Med. 2007;167:1130–1136
  10. Bang H, Vupputuri S, Shoham DA, et al. SCreening for Occult REnal Disease (SCORED): A simple prediction model for chronic kidney disease. Arch Intern Med. 2007;167:374–381
  11. Gooch K, Culleton BF, Manns BJ, et al. NSAID use and progression of chronic kidney disease. Am J Med. 2007;120(280):e1–e7
  12. Bleyer AJ, Shemanski LR, Burke GL, Hansen KJ, Appel RG. Tobacco, hypertension, and vascular disease: Risk factors for renal functional decline in an older population. Kidney Int. 2000;57:2072–2079
  13. Haroun MK, Jaar BG, Hoffman SC, Comstock GW, Klag MJ, Coresh J. Risk factors for chronic kidney disease: A prospective study of 23,534 men and women in Washington County, Maryland. J Am Soc Nephrol. 2003;14:2934–2941
  14. Ridker PM, Brown NJ, Vaughan DE, Harrison DG, Mehta JL. Established and emerging plasma biomarkers in the prediction of first atherothrombotic events. Circulation. 2004;109:IV6–IV19
  15. Pai JK, Pischon T, Ma J, et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med. 2004;351:2599–2610
  16. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207
  17. Diamond JR. Analogous pathobiologic mechanisms in glomerulosclerosis and atherosclerosis. Kidney Int Suppl. 1991;31:S29–S34
  18. Keane WF, Kasiske BL, O'Donnell MP. Lipids and progressive glomerulosclerosis (A model analogous to atherosclerosis). Am J Nephrol. 1988;8:261–271
  19. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868–874
  20. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med. 1998;339:1448–1456
  21. Shlipak MG, Katz R, Kestenbaum B, Fried LF, Siscovick D, Sarnak MJ. Clinical and subclinical cardiovascular disease and kidney function decline in the elderly. Atherosclerosis. 2008;Aug 26 [Epub ahead of print]
  22. Knight EL, Rimm EB, Pai JK, et al. Kidney dysfunction, inflammation, and coronary events: A prospective study. J Am Soc Nephrol. 2004;15:1897–1903
  23. Muntner P, Hamm LL, Kusek JW, Chen J, Whelton PK, He J. The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease. Ann Intern Med. 2004;140:9–17
  24. Menon V, Greene T, Wang X, et al. C-Reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease. Kidney Int. 2005;68:766–772
  25. Stuveling EM, Hillege HL, Bakker SJ, Gans RO, De Jong PE, De Zeeuw D. C-Reactive protein is associated with renal function abnormalities in a non-diabetic population. Kidney Int. 2003;63:654–661
  26. Shlipak MG, Fried LF, Crump C, et al. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation. 2003;107:87–92
  27. Erlinger TP, Tarver-Carr ME, Powe NR, et al. Leukocytosis, hypoalbuminemia, and the risk for chronic kidney disease in US adults. Am J Kidney Dis. 2003;42:256–263
  28. Fried L, Solomon C, Shlipak M, et al. Inflammatory and prothrombotic markers and the progression of renal disease in elderly individuals. J Am Soc Nephrol. 2004;15:3184–3191
  29. Tonelli M, Sacks F, Pfeffer M, Jhangri GS, Curhan G. Cholesterol and Recurrent Events Trial I (Biomarkers of inflammation and progression of chronic kidney disease). Kidney Int. 2005;68:237–245
  30. Bash LD, Erlinger TP, Coresh J, Marsh-Manzi J, Folsom AR, Astor BC. Inflammation, hemostasis, and the risk of kidney function decline in the Atherosclerosis Risk in Communities (ARIC) study. Am J Kidney Dis. 2008;53:596–605
  31. Winkelmayer WC, Schneeweiss S, Mogun H, Patrick AR, Avorn J, Solomon DH. Identification of individuals with CKD from Medicare claims data: A validation study. Am J Kidney Dis. 2005;46:225–232
  32. Zoccali C. Biomarkers in chronic kidney disease: Utility and issues towards better understanding. Curr Opin Nephrol Hypertens. 2005;14:532–537
  33. Savoia C, Schiffrin EL. Inflammation in hypertension. Curr Opin Nephrol Hypertens. 2006;15:152–158
  34. Lloyd-Jones DM, Liu K, Tian L, Greenland P. Narrative review: Assessment of C-reactive protein in risk prediction for cardiovascular disease. Ann Intern Med. 2006;145:35–42
  35. Verhave JC, Gansevoort RT, Hillege HL, Bakker SJ, De Zeeuw D, de Jong PE. An elevated urinary albumin excretion predicts de novo development of renal function impairment in the general population. Kidney Int Suppl. 2004;92:S18–S21
  36. Halbesma N, Kuiken DS, Brantsma AH, et al. Macroalbuminuria is a better risk marker than low estimated GFR to identify individuals at risk for accelerated GFR loss in population screening. J Am Soc Nephrol. 2006;17:2582–2590
  37. Festa A, D'Agostino R, Howard G, Mykkanen L, Tracy RP, Haffner SM. Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: The Insulin Resistance Atherosclerosis Study. Kidney Int. 2000;58:1703–1710

PII: S0272-6386(09)00028-6

doi: 10.1053/j.ajkd.2009.01.001

American Journal of Kidney Diseases
Volume 53, Issue 4 , Pages 572-575 , April 2009

Article Tools